NewAmsterdam Pharma Co N.V.
For the period ended Dec 31, 2025. Filed Feb 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 18, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NewAmsterdam Pharma Company N.V. | ||
| Date: February 18, 2026 | By: | /s/ Michael Davidson |
|---|---|---|
| Michael Davidson, M.D. | ||
| Chief Executive Officer and Director | ||
| (Principal Executive Officer) | ||
| Date: February 18, 2026 | By: | /s/ Ian Somaiya |
| Ian Somaiya | ||
| Chief Financial Officer | ||
| (Principal Financial Officer) | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Davidson and Ian Somaiya, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her, and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Michael Davidson | ||
| Dr. Michael Davidson | Chief Executive Officer and Director (Principal Executive Officer) | February 18, 2026 |
| /s/ Ian Somaiya | ||
| Ian Somaiya | Chief Financial Officer(Principal Financial Officer) | February 18, 2026 |
| /s/ Louise Kooij | ||
| Louise Kooij | Chief Accounting Officer(Principal Accounting Officer) | February 18, 2026 |
| /s/ William H. Lewis | ||
| William H. Lewis | Chairman of the Board of Directors | February 18, 2026 |
| /s/ Adele Gulfo | ||
| Adele Gulfo | Director | February 18, 2026 |
| /s/ Wouter Joustra | ||
| Wouter Joustra | Director | February 18, 2026 |
| /s/ John Kastelein | ||
| Dr. John Kastelein | Chief Scientific Officer and Director | February 18, 2026 |
| /s/ Louis Lange | ||
| Dr. Louis Lange | Director | February 18, 2026 |
| /s/ Mark C. McKenna | ||
| Mark C. McKenna | Director | February 18, 2026 |
| /s/ John W. Smither | ||
| John W. Smither | Director | February 18, 2026 |
| /s/ James N. Topper | ||
| Dr. James N. Topper | Director | February 18, 2026 |
| /s/ Janneke van der Kamp | ||
| Janneke van der Kamp | Director | February 18, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.